September 9, 2024

Procyrion Announces Appointment of Lucas Buchanan to Board of Directors

Lucas is an Industry veteran who brings expertise in commercialization, operations, business development, and finance to Procyrion as it continues to focus on its DRAIN-HF pivotal IDE trial and begins preparation for US commercialization of its Aortix percutaneous mechanical circulatory support (pMCS) technology.

Read More
ALL
Press Releases
Articles
Publications
Awards

Fierce Biotech

Procyrion Recognized in Fierce Medtech's Fierce15 of 2023

Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated.

March 4, 2024
  • Articles
  • Articles

Press Release

Procyrion Closes $57.7 Million in Series E Financing

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing.

February 5, 2024
  • Press Releases

Press Release

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company's IDE pivotal trial.

November 30, 2023
  • Press Releases

Press Release

Procyrion Secures New Medicare Payment Codes Applicable to its Aortix™ Percutaneous Mechanical Circulatory Support Technology

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support (pMCS) technology.

September 7, 2023
  • Press Releases

Press Release

Aortix™ Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Procyrion, Inc. announced today that use of its Aortix™ percutaneous mechanical circulatory support (pMCS) device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure (ADHF) and worsening renal function, which is known as cardiorenal syndrome (CRS).

March 21, 2023
  • Press Releases

Press Release

Procyrion Announces Successful First-in-Human Cases with Aortix™ Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery

Procyrion announces successful first-in-human cases with Aortix™ pump to prevent acute kidney injury in patients undergoing cardiac surgery. Study adds to the growing body of data for the Aortix™ pump, which will be featured in a presentation at the Technology and Heart Failure Therapeutics conference in March.

February 22, 2023
  • Press Releases

Press Release

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

November 2, 2021
  • Press Releases
Older Posts
The Aortix™ device is currently in the research and development phase and is not available for sale in any country.
Caution: Investigational Device. Limited by Federal Law to Investigational Use. Exclusively for Clinical Investigations in the European Union.

Links

HomeClinical TrialsOverviewTeamNewsCareersReferencesDisclaimer & Terms of UseContact

LATEST NEWS

September 2024
Press Release
Procyrion Announces Appointment of Lucas Buchanan to Board of Directors
March 2024
Fierce Biotech
Procyrion Recognized in Fierce Medtech's Fierce15 of 2023
February 2024
Press Release
Procyrion Closes $57.7 Million in Series E Financing

ABOUT US

Procyrion is a team of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists.

Our dedicated team is working to address the unmet clinical needs of heart failure patients through the development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device.

Copyright © 2021 - 2025 Procyrion, Inc.
Disclaimer & Terms of Use
Aortix™ is for investigational use only and is not for sale in the United States.